
News
News & Events
-
September 20, 2023
The CPP Consortium Welcomes Biohaven as its Newest Member
The Critical Path for Parkinson’s Consortium is excited to welcome Biohaven as its newest member. Biohaven is a biopharmaceutical company aimed at discovering and developing novel life-changing therapies for people living with neurological and neuropsychiatric diseases by collaborating with leaders in scientific discovery and medicine. CPP is excited to work with Biohaven as one of many new members from...... -
August 25, 2023
C-Path’s Romero Appears on The BioCentury Show
Klaus Romero, Chief Science Officer at Critical Path Institute, occupies a rare role in the industry, as the top scientist in an organization whose mission is to solve industry-wide bottlenecks in drug development, with a path that leads directly to endorsement by FDA and other regulatory bodies. On the latest episode of The BioCentury Show, Romero...... -
August 25, 2023
C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium
AcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an initial focus on Parkinson’s disease. To achieve this, AcureX leverages a first-in-class peripheral drug-responsive biomarker assays to molecularly define and segment patients in combination with novel disease-modifying therapeutics. AcureX is ushering in a new era of precision medicine...... -
August 25, 2023
C-Path’s Role in IHI Call 4: Enhancing Rare Disease Clinical Trials
This memo outlines how C-Path can contribute as a key strategic regulatory partner to the Innovative Health Initiative’s (IHI) call 4, “Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases.” We encourage potential partners to review the memo and reach out as early as possible to rdcadap@c-path.org with interest. On 27 July 2023, the...... -
August 22, 2023
C-Path Welcomes ObvioHealth
C-Path is proud to welcome ObvioHealth, a virtual research organization (VRO), as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Comprised of 23 firms that provide electronic data collection technologies and services for capturing patient-reported outcome and other clinical outcome assessment data in clinical trials, eCOA Consortium members collaborate in a pre-competitive......